The company reported a loss of 13 cents a share, compared to a loss of 26 cents a share in the same period one year earlier. This narrowly beat the consensus estimate of a loss of 14 cents a share by a penny. Revenue increased 20.3% year over year to $46.3 million, which beat the consensus estimate of $46.06 million.
Sequenom also disclosed in a regulatory filing that Chief Medical Officer Allan Bombard told the company he would retire from Sequenom as of its next annual stockholders' meeting on June 10.
The stock was up 13.07% to $3.02 at noon.
SQNM data by YCharts
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.